# Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

> **NCT05794659** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Aston Sci. Inc.** · enrollment: 98 (estimated)

## Conditions studied

- Advanced Ovarian Cancer

## Interventions

- **BIOLOGICAL:** AST-201
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Placebo
- **DRUG:** rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)

## Key facts

- **NCT ID:** NCT05794659
- **Lead sponsor:** Aston Sci. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-15
- **Primary completion:** 2025-11-15
- **Final completion:** 2027-11-15
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05794659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05794659, "Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05794659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*